Life Sciences Ophthalmic Gene Therapies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Ophthalmic Gene Therapies
1.1 - About Life Sciences Ophthalmic Gene Therapies sector
Companies in Life Sciences Ophthalmic Gene Therapies research, develop, and commercialize genetic medicines targeting retinal and other ocular diseases. They engineer viral vectors and delivery methods tailored to the eye, advance candidates through preclinical and clinical stages, and partner for manufacturing and distribution. Their value proposition is restoring or preserving vision with durable, one-time treatments and de-risked development programs aligned with regulatory pathways.
Typical offerings include AAV-based gene replacement therapies for inherited retinal diseases, CRISPR/Cas editing constructs to correct pathogenic mutations, and RNAi or antisense approaches to modulate aberrant expression. Vendors design retina-targeted capsids, optimize intravitreal and subretinal delivery, and develop optogenetic modalities for advanced degeneration. They support GMP viral vector manufacturing, translational pharmacology, IND-enabling studies, and clinical trial design with ocular imaging, functional endpoints, and long-term safety monitoring.
Primary customers include ophthalmology-focused biopharmaceutical companies, genetic medicine innovators seeking ocular indications, and academic medical centers running translational programs. These providers enable buyers to expand pipelines into inherited retinal disorders, accelerate IND-to-approval timelines, reduce delivery and manufacturing risk, and demonstrate durable functional vision outcomes. They also support regulatory readiness, payer evidence generation, and scalable commercialization across retina specialist networks.
2. Buyers in the Life Sciences Ophthalmic Gene Therapies sector
2.1 Top strategic acquirers of Life Sciences Ophthalmic Gene Therapies companies
4D Molecular Therapeutics
- Description: Provider of clinical-stage genetic medicine therapies built on a proprietary Therapeutic Vector Evolution platform that creates customized AAV vectors and supports a diverse pipeline of gene therapy candidates aimed at treating large-market and rare diseases.
- Key Products:
- Therapeutic Vector Evolution platform: Combines directed evolution with ~1 billion synthetic capsid sequences to engineer AAV vectors that efficiently transduce target tissues while reducing immunogenicity
- 4D-125: A Phase 1/2 gene therapy candidate employing evolved AAV vectors to treat X-linked retinitis pigmentosa by delivering therapeutic genes via routine, minimally invasive ocular administration
- 4D-110: Phase 1 gene therapy designed for choroideremia, using targeted AAV capsids to reach diseased retinal cells and correct underlying genetic defects
- 4D-310: Phase 1/2 gene therapy for Fabry disease that delivers corrective genes to cardiac tissue through evolved vectors intended to overcome pre-existing antibodies and improve cardiac function.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Ophthalmic Gene Therapies sector
M&A buyer group 1: Ophthalmology
Lineage Cell Therapeutics
- Type: N/A
- Employees: ●●●●●
- Description: Provider of cell-based therapeutic solutions developing and manufacturing specialized, terminally differentiated human cells to replace or support dysfunctional cells in degenerative diseases, traumatic injuries and cancer, with clinical-stage programs targeting dry age-related macular degeneration, spinal cord injury, lung cancer and hearing loss.
- Key Products:
- Allogeneic Cell Therapy Programs for Neurological Conditions: Development and transplantation of specialized human cells to replace or support neurons lost to degenerative disease or injury, aiming to restore functional activity
- Allogeneic Cell Therapy Programs for Ophthalmic Conditions: Manufacture and delivery of functional ocular cells identical to natural counterparts to treat serious eye diseases by replacing dysfunctional cells
- Proprietary Cell-Based Technology Platform: Directed differentiation of well-characterized pluripotent cell lines along specific developmental lineages to generate desired functional cells for scalable off-the-shelf therapies
- Development
- Formulation
- Manufacturing and Delivery Capabilities: Integrated processes that design, produce and administer specialized human cells, enhancing efficiency and success probability for internal or partnered therapeutic programs.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Ophthalmic Gene Therapies sector
3.1 - Buyout funds in the Life Sciences Ophthalmic Gene Therapies sector
2.2 - Strategic buyer groups for Life Sciences Ophthalmic Gene Therapies sector
4 - Top valuation comps for Life Sciences Ophthalmic Gene Therapies companies
4.2 - Public trading comparable groups for Life Sciences Ophthalmic Gene Therapies sector
Valuation benchmark group 1: Cell and Gene Therapy Biopharma Companies
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions